Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Both obesity and sarcopenia are frequently associated in ageing, and together may promote the progression of related conditions such as diabetes and frailty. However, little is known about the pathophysiological mechanisms underpinning this association. Here we show that systemic alanine metabolism is linked to glycaemic control. We find that expression of alanine aminotransferases is increased in the liver in mice with obesity and diabetes, as well as in humans with type 2 diabetes. Hepatocyte-selective silencing of both alanine aminotransferase enzymes in mice with obesity and diabetes retards hyperglycaemia and reverses skeletal muscle atrophy through restoration of skeletal muscle protein synthesis. Mechanistically, liver alanine catabolism driven by chronic glucocorticoid and glucagon signalling promotes hyperglycaemia and skeletal muscle wasting. We further provide evidence for amino acid–induced metabolic cross-talk between the liver and skeletal muscle in ex vivo experiments. Taken together, we reveal a metabolic inter-tissue cross-talk that links skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. Elevated hepatic alanine catabolism is shown to promote hyperglycaemia and reduce skeletal muscle protein synthesis, thereby linking sarcopenia with hyperglycaemia in the context of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Sarcopenic obesity: A new category of obesity in the elderly
Zamboni, M., Mazzali, G., Fantin, F., Rossi, A., & Di Francesco, V. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.10.002 · Cited by 953
Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Lee, J. S., Kuller, L. H., Boudreau, R., de Rekeneire, N., Harris, T. B., Kritchevsky, S., Tylavsky, F. A., Nevitt, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0264 · Cited by 778
Srikanthan, P., Hevener, A. L., & Karlamangla, A. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010805 · Cited by 600
Hormonal regulation of hepatic glucose production in health and disease
Lin, H. V., & Accili, D. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.003 · Cited by 429
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Tian, S., & Xu, Y. (2016) · Geriatrics & Gerontology International · doi:10.1111/ggi.12579 · Cited by 274
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245
Grøntved, L., John, S., Baek, S., Liu, Y., Buckley, J. R., Vinson, C., Aguilera, G., & Hager, G. L. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.106 · Cited by 229
Splanchnic regulation of glucose production
Wahren, J., & Ekberg, K. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093806 · Cited by 185
Cited by
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102665 · Cited by 21
Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Metadata
- Authors
- Okun, J. G., Rusu, P. M., Chan, A. Y., Wu, Y., Yap, Y. W., Sharkie, T., Schumacher, J., Schmidt, K. V., Roberts-Thomson, K. M., Russell, R. D., Zota, A., Hille, S., Jungmann, A., Maggi, L., Lee, Y., Blüher, M., Herzig, S., Keske, M. A., Heikenwalder, M., Müller, O. J., & Rose, A. J.
- Venue
- Nature Metabolism
- Published
- 2021-03-18
- Volume
- 3
- Issue
- 3
- Pages
- 394-409
- ISSN
- 2522-5812 (ISSN-L)
- OpenAlex
- W3138014196
- Cited by
- 116
- References
- 18
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. https://app.cochat.ai/papers/10.1038/s42255-021-00369-9
- The paper
- Okun, J. G., Rusu, P. M., Chan, A. Y., Wu, Y., Yap, Y. W., Sharkie, T., Schumacher, J., Schmidt, K. V., Roberts-Thomson, K. M., Russell, R. D., Zota, A., Hille, S., Jungmann, A., Maggi, L., Lee, Y., Blüher, M., Herzig, S., Keske, M. A., Heikenwalder, M., . . . Rose, A. J. (2021). Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. Nature Metabolism. https://doi.org/10.1038/s42255-021-00369-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.